Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. Get Wall ...

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. Get Pro-Level ...

CureVac (NASDAQ:CVAC – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself. CureVac revealed yesterday that ...

GlaxoSmithKline and CureVac are to begin developing a next generation vaccine targeting emerging variants of the coronavirus – although it is unlikely to be ready until at least next year.

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...